The Noida-Greater Noida healthcare market is rapidly emerging as one of North India’s most attractive hospital growth corridors, driven by strong population growth, expanding corporate activity, and a widening catchment area that extends beyond city boundaries. Despite ongoing capacity additions, industry estimates suggest the region remains significantly underpenetrated, with only around 4,500 super-specialty beds serving Noida, Greater Noida, and adjoining cities in Western Uttar Pradesh.
Over the past five years, the region’s population has grown at a 5.4% compound annual rate to approximately 1.3 million, supported by the expansion of IT services, manufacturing, electronics, data centers, and financial services. Affordable housing, improving connectivity, and rising employment opportunities have transformed Noida from a satellite city into a self-sustaining urban center. This demographic shift is creating sustained demand for healthcare services, particularly in cardiology, oncology, diabetes care, maternity, pediatrics, and chronic disease management.
Hospital operators are already witnessing the benefits of these structural tailwinds. Occupancy levels across major facilities continue to rise, while revenue growth remains robust. Mature assets in the region are operating at high utilization rates and delivering healthy profitability, while newly commissioned facilities are scaling up faster than expected, aided by strong brand recognition and increasing patient inflows. Notably, patient demand is no longer confined to Noida residents, with significant traffic originating from East Delhi and neighboring cities such as Ghaziabad, Bulandshahr, and Aligarh.
A key feature of the market is the under-penetration of advanced healthcare services, including organ transplants, robotic-assisted procedures, and critical care. As healthcare providers continue investing in centers of excellence and specialty capabilities, the region is expected to witness further improvements in treatment complexity and patient retention.
Infrastructure development is also strengthening the long-term outlook. Enhanced metro connectivity, expressway networks, and the upcoming airport ecosystem are supporting residential and industrial expansion while opening avenues for domestic and eventually international medical tourism.
However, the availability and cost of specialist doctors remain critical challenges. As multiple hospital operators expand simultaneously, competition for experienced medical talent has intensified, putting pressure on costs and profitability. Industry participants are increasingly focusing on physician retention, productivity enhancement, and case-mix optimization to mitigate these pressures.
Overall, demand growth continues to outpace capacity additions, suggesting that the Noida-Greater Noida healthcare market remains far from saturation. With rising occupancy, improving operational leverage, and sustained healthcare demand, the region appears well positioned for continued expansion over the medium term.
Medanta: Buy | Target Rs 1490
Medanta is witnessing healthy demand across both mature and developing hospitals, supported by higher patient volumes, improving realizations, and ongoing capacity expansion. The company remains focused on optimizing occupancy, adding doctor talent, and scaling up specialties across key hospitals, while Noida is expected to achieve EBITDA breakeven in 2HFY27. Expansion into new markets such as Indore, Varanasi, Guwahati, Mumbai, and South Delhi, along with growing international patient inflows and healthcare ecosystem initiatives, is expected to support long-term growth. We remain positive on Medanta, supported by strong patient volume growth, ongoing hospital ramp-up, and an aggressive expansion pipeline. We estimate a robust 28% earnings CAGR over FY26-28, driven by scaling up of Noida, improving utilization across existing hospitals, and continued capacity additions.
Max Healthcare: Buy | Target Rs 1260
Max Healthcare operates a high-acuity multi-specialty hospital network complemented by diagnostics and homecare platforms, with growth supported by brownfield expansions, digital patient acquisition and rising tertiary-care penetration. Strong occupancy, improving specialty mix and disciplined capital deployment support resilient EBITDA per bed, while low leverage strengthens long-term earnings visibility. We expect brownfield ramp-up at Smart, Nanavati and Mohali to support near-term recovery, while the Gurgaon greenfield project is expected to contribute from FY28 despite commissioning delays. We project consolidated revenue/EBITDA/PAT CAGR of 14%/15%/20% over FY26-28, supported by capacity additions and operating leverage.
(The author is Siddhartha Khemka, Head of Research, Wealth Management, MOFSL)
(Disclaimer: Recommendations, suggestions, views, and opinions given by experts are their own. These do not represent the views of the Economic Times)
